Osteoarthritis: New Insights. Part 2: Treatment Approaches
- Conference Chair: David T. Felson, MD, MPH;
- Conference Organizer: Reva C. Lawrence, MPH;
- Discussants: Marc C. Hochberg, MD, MPH;
- Timothy McAlindon, MD, MPH;
- Paul A. Dieppe, MD;
- Marian A. Minor, PT, PhD;
- Steven N. Blair, PED;
- Brian M. Berman, MD;
- James F. Fries, MD;
- Morris Weinberger, PhD;
- Kate R. Lorig, RN, DrPH;
- Joshua J. Jacobs, MD; and
- Victor Goldberg, MD
-
From Boston University School of Medicine, Boston, Massachusetts; National Institute of Arthritis and Musculoskeletal and
Skin Diseases, National Institutes of Health, Bethesda, Maryland; University of Maryland School of Medicine, Baltimore, Maryland;
MRC Health Services Research Collaboration, University of Bristol, Bristol, United Kingdom; University of Missouri, Columbia,
Missouri; Cooper Institute for Aerobics Research, Dallas, Texas; Stanford University School of Medicine, Palo Alto, California;
Indiana University, Indianapolis, Indiana; Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois; and Case Western
Reserve University, Cleveland, Ohio.
-
Figure 1. The white circles represent the effect size of each glucosamine trial; 0 represents no effect relative to placebo.
Horizontal lines represent 95% CIs. The white diamond represents aggregate results (with 95% CI) for glucosamine trials. The
black circles and diamonds represent the same features for chondroitin. Data from reference . Meta-analysis of placebo-controlled trials of glucosamine and chondroitin in osteoarthritis.48
-
Figure 2. Pain was measured by using a visual analogue scale in which patients were asked to quantify their current pain.
The depression score is derived from Center for Epidemiologic Studies–Depression symptoms scale. Data from reference . Decreases in pain, depression, and physician visits in 401 patients after 4 months (white bars) and 4 years (shaded bars)
of an arthritis self-management program.107
- Copyright ©2004 by the American College of Physicians
-
Ann Intern Med
November 7, 2000
vol. 133
no. 9
726-737
RSS Feeds
View larger version:Figure 1. The white circles represent the effect size of each glucosamine trial; 0 represents no effect relative to placebo. Horizontal lines represent 95% CIs. The white diamond represents aggregate results (with 95% CI) for glucosamine trials. The black circles and diamonds represent the same features for chondroitin. Data from reference . Meta-analysis of placebo-controlled trials of glucosamine and chondroitin in osteoarthritis.48
View larger version:Figure 2. Pain was measured by using a visual analogue scale in which patients were asked to quantify their current pain. The depression score is derived from Center for Epidemiologic Studies–Depression symptoms scale. Data from reference . Decreases in pain, depression, and physician visits in 401 patients after 4 months (white bars) and 4 years (shaded bars) of an arthritis self-management program.107
